The Role of Human Monoclonal Antibody Specificity and Avidity in the Protection Against Gram-negative Bacteria
Despite the use of increasingly potent antimicrobial drugs, an increase of fatal bacteria infections has been noted (Baumgartner and Glauser 1987, Cryz 1987). This failure of antibiotic treatment urges the search for alternative therapies. The use of passive immunotherapy with human monoclonal antibodies (MAb) is generally accepted as the most promising aproach (Teng et al. 1985, Larrick et al. 1986, Masuho 1988). However, the intricacies of human MAb generation may be responsible for the fact that so little progress has been reported in this field.
KeywordsHuman Monoclonal Antibody Conjugate Vaccine Protective Capacity High Avidity Competitive Binding Assay
Unable to display preview. Download preview PDF.
- Baumgartner JD, Heumann D, Gerlain J, Weinbreck P, Grau GE, Glauser MP (1990) Association between protective efficacy of antilipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor a and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med 171: 889–896PubMedCrossRefGoogle Scholar
- Bruderer U, Fürer E, Cryz Jr SL, Lang AB (1990) Differences in the protective capacity of naturally occurring and deliberately induced human anti-Pseudomonas antibodies. Manuscript submittedGoogle Scholar
- Lang AB, Fürer E, Senyk G, Larrick JW, Cryz Jr SL (1990 a) Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Human Antibodies and Hybridomas 1 (in press)Google Scholar
- Lang AB, Bruderer U, Fürer E, LarrickJW, Cryz Jr SL (1990 b) Immunoprotective capacities of human and murine monoclonal antibodies recognizing serotype specific and common determinants of gram-negative bacteria. In: Borrebaeck C, Larrick JW (eds) Therapeutic monoclonal antibodies. Stockton Press, New York (in press)Google Scholar